Treatment of primary CNS lymphoma by Roth, P et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Treatment of primary CNS lymphoma
Roth, P; Stupp, R; Eisele, G; Weller, M
Abstract: OPINION STATEMENT: Primary central nervous system lymphoma is a particular challenge
in clinical neuro-oncology. In contrast to most other malignant brain tumors, it may be considered a cur-
able disease at least in younger patients who can tolerate intensive treatment regimens. Yet, therapeutic
progress has been limited with little measurable improvement in outcome over the last two decades, mainly
due to the low incidence of this tumor, which impedes the execution of large randomized clinical trials,
and the failure of most large cooperative groups to conduct such trials. Whenever possible, high-dose
methotrexate (HD-MTX) is the backbone of the therapeutic regimen. Response rates can be increased
by the addition of second agents like ifosfamide or cytarabine, however, their impact on overall survival is
less clear. Similarly, the use of the anti-CD20 antibody rituximab, commonly used in the treatment of B
cell lymphomas outside the CNS, remains controversial and has not been examined in adequate clinical
trials. The prognosis of patients, who do not qualify for HD-MTX-based chemotherapy, is considerably
poorer. Radiation therapy is an active treatment with high response rates but does typically not result
in long-lasting remissions. It remains an important therapeutic option as a salvage therapy in patients
progressing on or no longer responding to HD-MTX-based treatment. The combination of HD-MTX and
radiation therapy does not prolong overall survival. It is associated with significant neurotoxicity, and
it should be avoided. Another matter of debate is whether consolidation therapy by other means, such
as high-dose chemotherapy followed by stem cell support, is the most promising regimen. Given these
numerous uncertainties, neuro-oncologists should strive for a treatment of PCNSL patients within clinical
trials to allow for the development of improved therapeutic regimens.
DOI: 10.1007/s11940-013-0277-y
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-95410
Accepted Version
Originally published at:
Roth, P; Stupp, R; Eisele, G; Weller, M (2014). Treatment of primary CNS lymphoma. Current Treat-
ment Options in Neurology, 16(1):277. DOI: 10.1007/s11940-013-0277-y
SPRINGERLINK HEADER: 
NEURO-ONCOLOGY (R SOFFIETTI, SECTION EDITOR) 
 
Treatment of Primary CNS Lymphoma 
 
Patrick Roth1,3, Roger Stupp2,3, Günter Eisele1,3 and Michael Weller1,3 
 
 
Affiliations: Departments of 1Neurology and 2Oncology and 3Brain Tumor Center Zurich, 
University Hospital Zurich, Switzerland 
 
 
 
Correspondence: Dr. Patrick Roth, Department of Neurology, University Hospital Zurich, 
Frauenklinikstrasse 26, 8091 Zurich, Switzerland, Tel.: +41 (0)44 255 5511, Fax: +41 
(0)44 255 4507, E-mail: patrick.roth@usz.ch 
 
 
Running title: Therapeutic management of PCNSL 
 
Keywords: Primary CNS lymphoma; Chemotherapy; Methotrexate; Rituximab; 
Temozolomide; Irradiation; Neurotoxicity; Treatment; Steroids; Intrathecal therapy 
 
Opinion statement 
 
Primary central nervous system lymphoma is a particular challenge in clinical 
neurooncology. In contrast to most other malignant brain tumors, it may be considered a 
curable disease at least in younger patients who can tolerate intensive treatment 
regimens. Yet, therapeutic progress has been limited with little measurable improvement 
in outcome over the last two decades, mainly due to the low incidence of this tumor 
which impedes the execution of large randomized clinical trials, and the failure of most 
large cooperative groups to conduct such trials. Whenever possible, high-dose 
methotrexate (HD-MTX) is the backbone of the therapeutic regimen. Response rates can 
be increased by the addition of second agents like ifosfamide or cytarabine, however, 
their impact on overall survival is less clear. Similarly, the use of the anti-CD20 antibody 
rituximab, commonly used in the treatment of B cell lymphomas outside the CNS 
remains controversial and has not been examined in adequate clinical trials. The 
prognosis of patients, who do not qualify for HD-MTX-based chemotherapy, is 
considerably poorer. Radiation therapy is an active treatment with high response rates, 
but does typically not result in long-lasting remissions. It remains an important 
therapeutic option as a salvage therapy in patients progressing on or no longer 
responding to HD-MTX-based treatment. The combination of HD-MTX and radiation 
therapy does not prolong overall survival, is associated with significant (neuro-)toxicity 
and should be avoided. Whether consolidation therapy by other means such as high-
dose chemotherapy followed by stem cell support is the most promising regimen, is 
another matter of debate. Given these numerous uncertainties, neuro-oncologists should 
strive for a treatment of PCNSL patients within clinical trials to allow for the development 
of improved therapeutic regimens. 
 
 
 
 
INTRODUCTION 
 
Primary central nervous system lymphoma (PCNSL) is a rare extranodal form of Non-
Hodgkin lymphoma (NHL). Registry data from the United States report that only 2.2% of 
all intracranial tumors are lymphomas [1]. Immunodeficiency (e.g. congenital or acquired 
such as human immunodeficiency virus [HIV] infection) is associated with an increased 
risk for the development of PCNSL. The improvement of antiretroviral therapy resulted in 
a decreased incidence of PCNSL in immunocompromised patients translating in fewer 
young patients affected with PCNSL. This contrasts a continued increase in men and 
women aged 65 and older for reasons yet to be determined [2]. In immunocompetent 
patients the median age at diagnosis is about 60 years. 
PCNSL can involve all parts of the CNS including supra- and infratentorial 
compartments, spinal cord, meninges and cerebrospinal fluid (CSF). Finally, intraocular 
manifestation, either alone, then referred to as primary intraocular lymphoma (PIOL) or 
often associated with CNS involvement can occur. Patients with PCNSL may present 
with various clinical symptoms and signs. The extent of personality changes, cognitive 
disturbances and focal neurological deficits will depend on tumor size, localization and 
extent of the peritumoral edema. Intraocular involvement may cause blurred vision or 
other complaints.  
Computed tomography (CT) or preferentially magnetic resonance imaging (MRI) are 
used as imaging techniques with single or multiple supratentorial homogeneous contrast-
enhancing tumor masses as a typical finding [3]. There are no specific features, which 
allow a reliable differentiation between PCNSL and other primary or secondary brain 
tumors as well as inflammatory lesions. The use of ultrasmall superparamagnetic iron 
oxide (USPIO) nanoparticles may improve the MRI diagnosis of PCNSL [4]. This 
technique, however, has not yet entered the clinical routine examination. Similarly, the 
value of positron emission tomography (PET) imaging using different tracers such as 18F-
fluordeoxyglucose (18F-FDG) or 11C-methionine for the diagnosis and monitoring of 
PCNSL has remained questionable [5-7]. Upon diagnosis of a lymphoma in the CNS, the 
diagnosis of PCNSL can only be rendered after exclusion of tumor manifestations 
outside the CNS. The detection of lymphoma cells in the CSF, also referred to as 
meningeal dissemination, or in the eye and cranial nerves is still compatible with PCNSL. 
However, staging is recommended in every patient to exclude other lymphoma 
manifestations [8]. This is typically done by chest, abdomen and pelvis CT. Whether 
FDG-PET-based visualization results in increased sensitivity remains unclear [9]. Ocular 
infiltration must be ruled out by an appropriate ophthalmologic diagnostic. Vitrectomy 
followed by histopathological assessment of the aspirate is used to definitely verify or 
exclude lymphoma manifestations in the eye [10]. Bone marrow diagnostics may reveal 
the presence of tumors cells which, however, does not change the therapeutic approach 
in the absence of other systemic lymphoma manifestations [11]. Further 
recommendations of the International Extranodal Lymphoma Study Group (IELSG) 
include a lumbar puncture followed by CSF examination and testicular ultrasound in 
older men to exclude the presence of testicular lymphoma metastatic to brain [8].  
Histopathological assessment of PCNSL tissue results in the diagnosis of a diffuse large 
B cell lymphoma (DLBCL) in about 90% of all patients. These tumors typically express 
the B cell marker CD20, a prerequisite for consideration of treatment with the monoclonal 
antibody rituximab (see below). Standard cytology from body fluids such as vitreous or 
CSF may be broadened using flow cytometry analysis as well as PCR diagnostics of the 
rearranged immunoglobulin heavy-chain genes. Histopathological features as well as 
pitfalls in the diagnosis of PCNSL have been reviewed elsewhere [12]. CNS lymphoma 
with a histological diagnosis other than DLBCL is rare, including low-grade lymphomas 
and lymphomas of T cell origin as very uncommon findings [13, 14]. 
Because of the variable course of the disease, several attempts have been made to 
group patients into different clinical prognostic groups which may help to estimate the 
clinical evolution. The “Memorial Sloan-Kettering Cancer Center prognostic model” 
published in 2006 is based on a large cohort of PCNSL patients [15]. Patients being 
younger than 50 years had by far the best outcome. In the group of patients aged 50 or 
older, the performance status allowed for further separation between 2 groups with 
patients being 50 years or older and a Karnofsky performance status (KPS) below 70 
having the worst prognosis. A more comprehensive prognostic score was proposed by 
the IELSG using not only age and performance status but also elevated lactate 
dehydrogenase (LDH) and CSF protein levels as additional parameters which are 
associated with poor outcome [16]. Furthermore, the involvement of “deep brain 
structures” was determined as a negative factor and included in the prognostic 
assessment. This allowed for a separation of 3 patient groups which differ in their 
prognosis.  
 
TREATMENT 
 
Similar to many other brain tumors, the available treatment modalities for PCNSL 
comprise surgery, irradiation and chemotherapy, with a clear focus on the latter 2 
options. The agents or regimens (e.g. CHOP) commonly used to treat systemic 
lymphoma have no or only marginal activity in PCNSL [17]. There are probably several 
reasons including different biological properties of the tumors cells and the presence of 
the blood-brain barrier that impedes the penetration of many chemotherapeutics into the 
brain. Despite some progress within the last years, many important questions regarding 
the most effective treatment for PCNSL remain still under debate. The rarity of PCNSL 
precludes the rapid execution of well-designed clinical trials with reasonable patient 
numbers and does not allow for rapid evaluation of different treatment regimens. Still, the 
publication of 2 larger randomized trials within the last years has shown that such studies 
are feasible and should be pursued within the next years [18, 19].  
 
Surgery 
 
The intention of surgery has been purely diagnostic for decades. However, an unplanned 
subgroup analysis of the G-PCNSL-SG1 dataset, comprising several hundred patients, 
revealed that complete resection may be associated with a better outcome [20]. These 
findings are in contrast to very small and older retrospective series that suggested a 
biopsy-only approach. However, surgical techniques have improved and intra-operative 
imaging including ultrasound and MRI has advanced which might be the reason for this 
observation. Obviously, there will never be a randomized clinical trial comparing 
resection with biopsy in patients with lesions suspicious for a cerebral lymphoma. 
Therefore, based on the currently available evidence, complete resection should be 
considered in case of single lesions which may be removed safely. In case of multiple 
lesions or localization of the tumor mass in an eloquent region of the brain, open or 
stereotactic-guided biopsy will remain the gold standard because of the overall low risk of 
complications of such a procedure.  
 
Radiation therapy 
 
Radiation therapy has been used for decades for the treatment of PCNSL, but its role 
has been diminishing over the last years. Treatment of PCNSL has traditionally been 
considered to require the whole brain as the target volume (WBRT). Standard WBRT 
doses are typically 40-50 Gray (Gy) with single fractions of not more than 2 Gy. 
Administration of higher doses does not result in prolonged disease control, but causes 
more neurotoxic side effects [21]. Trials which assessed radiotherapy compared with 
supportive care do not exist but there is no doubt that WBRT is active against PCNSL. 
However, although high response rates can be achieved, they are commonly short-
lasting. Furthermore, there has been increasing evidence that irradiation is associated 
with considerable neurotoxicity, particularly in combination with MTX-based 
chemotherapy and in elderly patients [22]. Major questions which have been addressed, 
but only partially resolved within the last years included the following: 
- Is there any role for dose-reduced irradiation? 
- Does consolidating radiation therapy after MTX-based chemotherapy prolong 
progression-free (PFS) and overall survival (OS)? 
- When irradiation is deferred in patients who achieve a complete remission (CR) 
by chemotherapy alone, is it still active as a salvage treatment? 
Several analyses indicate that the addition of WBRT to HD-MTX is associated with a 
considerable risk of cognitive impairment. In contrast, a profoundly lower incidence of 
neurotoxic effects is observed when HD-MTX was applied alone [23, 24]. Because of 
these problems, the concept of dose-reduced WBRT was developed aiming at avoiding 
cognitive side effects, but still being active as consolidation. A report by Shaw and 
colleagues indicated a lack of neurocognitive decline when patients received 
consolidating WBRT with 23.4 Gy in 1.8 Gy/fraction after HD-MTX-based chemotherapy 
[25]. Owing to the lack of a control group, a benefit of the consolidation treatment could 
not be determined. However, because of the futility of (higher) standard dose WBRT to 
prolong OS following MTX-based chemotherapy in the G-PCNSL-SG1 trial (see below), 
it can be anticipated that RT with a decreased dose will not provide more benefit in terms 
of survival unless an unusual dose response relationship of RT for PCNSL was 
postulated. When RT is deferred it is still active in the situation of tumor recurrence. A 
retrospective case collection comprising 48 patients demonstrated an overall response 
rate of 79% and a median OS of 16 months [26] suggesting that WBRT is an active 
treatment for patients with recurrent or refractory PCNSL.  
 
Chemotherapy 
 
Chemotherapy is regarded the treatment of first choice for patients newly diagnosed with 
PCNSL. Chemotherapy-only approaches can result in high response rates and, even 
more important, long-lasting remissions. There is a debate, however, on the most active 
compounds to be added to the established backbone of high-dose (HD)-MTX 
chemotherapy. The lack of benefit from many drugs which are used for the treatment of 
systemic lymphoma including the CHOP regimen is most likely due to their insufficient 
penetration of the blood-brain barrier [27].  
 
Methotrexate alone or in combination 
MTX doses that are commonly administered are in the range of 3 to 8 g/m2, typically 
infused over 3 hours in 2 week-intervals. Doses less than 3 g/m2 are probably too low to 
reach sufficient concentrations in the CSF to kill lymphoma cells [28, 29]. A dose of 8 
g/m2 MTX was frequently associated with the need for a dose reduction during the 
course of the treatment, mostly due to renal toxicity [30, 31]. Therefore, most 
investigators chose a dose of MTX in the range of 3-4 g/m2 for combined therapeutic 
approaches with additional drugs. Various combinations of MTX with other agents have 
been evaluated within the last 3 decades. However, the design of these corresponding 
reports, commonly either from retrospective case collections and limited size or both, and 
the data from few uncontrolled, but at least prospective series does not allow for final 
conclusions and precludes definition of a standard of care beyond HD-MTX (reviewed in 
[32]). In fact, there are only 4 randomized trials in PCNSL of which one was closed early 
for poor patient accrual. Drugs which have been frequently used in combination with 
MTX include cytarabine, ifosfamide, temozolomide, procarbazine, vincristine and 
rituximab. Various regimens have been assessed aiming at increasing response rates 
and duration of response. The only randomized trial comparing MTX alone (3.5 g/m2) 
with MTX (3.5 g/m2) plus high-dose cytarabine (four cycles of 2 g/m2) followed by WBRT 
as consolidation treatment in both arms demonstrated a superior response rate to the 
chemotherapy part in the MTX/cytarabine arm (CRR= 46%) compared to only 18% in the 
cohort of patients receiving MTX alone [19]. The disappointingly and exceptionally poor 
results of the single agent MTX are likely due to the fact that MTX was administered only 
every 3 weeks rather than the usual every 2 weeks, leading to a decreased and 
insufficient dose intensity. This is also reflected by the fact that only 15% of the patients 
in the MTX only arm experienced grade 3/4 hematological toxicity. There was also a 
trend towards prolonged survival with the combination (3 year OS: 46% vs. 32%). An 
analysis of the G-PCNSL-SG1 trial indicates that increased response rates do not 
necessarily translate into prolonged OS. In this study, the addition of ifosfamide to HD-
MTX resulted in increased CR rates but no superiority in terms of OS compared to HD-
MTX alone was observed. In line with these findings, a comprehensive Cochrane 
database review concluded that the addition of other drugs to MTX may result in 
increased response rates as well as prolonged PFS whereas the benefit on OS remains 
unclear. In contrast, toxicity is significantly higher with combined treatment regimens [33]. 
Therefore, randomized trials with higher patient numbers and longer follow-up are 
required to ultimately determine the benefit from polychemotherapy as opposed to HD-
MTX alone. 
 
Chemotherapy and additional radiotherapy 
 
Consolidating radiation therapy has been explored as an adjunct to chemotherapy for at 
least 20 years. There are numerous uncontrolled phase II studies exploring MTX-based 
regimens with additional WBRT resulting in variable response rates and survival data. 
These trials cannot be compared to each other because of their different designs [34-37]. 
However, it became clear that the addition of WBRT to chemotherapy is associated with 
considerable (neuro-)toxicity, particularly in elderly patients. Only in 2010, the results of 
the randomized G-PCNSL-SG1 trial which enrolled more than 500 patients with newly 
diagnosed PCNSL were published [18]. The addition of WBRT to MTX-based 
chemotherapy resulted in prolonged PFS (18 months for the WBRT group versus 12 
months for patient who did not receive WBRT) whereas no difference in OS was 
observed (32 and 37 months, respectively). The trial was criticized for the long time 
needed for patient accrual, the high number of patients lost to follow-up and specifically 
the fact that approximately 1 in 4 patients did eventually not adhere to the randomization 
result, an inherent problem if patients are randomized several months prior to the 
timepoint where randomization becomes effective. However, the per-protocol as well as 
the intention-to-treat analysis yielded similar results for the major outcome measures, 
indicating that irradiation can be deferred until relapse after MTX-based first-line therapy. 
WBRT retains its role as a valuable treatment option in patients who fail to respond 
sufficiently to initial chemotherapy or do not qualify for MTX-based treatment, but 
outcome in relapsed PCNSL is commonly poor and long-term survival after WBRT would 
likely to be long-term survival with cognitive impairment. 
 
Other approaches for consolidation therapy 
 
Because of the failure of WBRT to prolong OS when used as a consolidation treatment 
and the significant long-term toxicity associated with its administration, other strategies 
aiming at avoiding immediate irradiation have been evaluated. One of the most 
promising approaches is high-dose chemotherapy (HDC) with subsequent autologous 
stem cell transplantation (ASCT), while omitting WBRT. This concept that has emerged 
over the last 15 years may be a promising strategy, in particular for younger and fit 
patients. HDC followed by ASCT has been examined in relatively small and uncontrolled 
trials both in patients with newly diagnosed as well as refractory and recurrent PCNSL. 
Various conditioning therapies have been used including a combination of thiotepa 
together with busulfane or carmustine (BCNU) or the BEAM regimen (carmustine, 
etoposide, cytarabine, melphalan). Several smaller trials combined a HDC approach with 
additional irradiation yielding excellent survival results that, however, might be 
compromised by late neurotoxicity, again [38-40]. Overall, MTX-based chemotherapy 
followed by high-dose therapy with carmustine and thiotepa and subsequent ASCT with 
or without WBRT resulted in promising long-term survival with a 5-year OS of 70% [41]. 
Further studies reported promising results without significant neurotoxicity when HDC 
and subsequent ASCT were administered without additional WBRT [42-44].  
Another approach assessed induction chemotherapy with MTX, temozolomide and 
rituximab followed by consolidation with etoposide and high-dose cytarabine for patients 
who achieved stable disease or better after induction. The 2-year OS was 58% when all 
patients were analyzed and 93% in the cohort of patients who had qualified for and 
received consolidation therapy with etoposide and cytarabine without evidence of 
neurotoxicity [45]. This regimen was further evaluated within a multicenter study resulting 
in survival curves which display evidence of a plateau. The median OS had not yet been 
reached after a median follow-up of 4.9 years [46]. These results indicate that 
chemotherapy alone can result in excellent long-term survival. However, the potential 
benefit of polychemotherapy and HDC/ASCT compared to standard chemotherapy alone 
needs to be confirmed in randomized trials.  
 
Other drugs 
 
In contrast to the unquestionable importance of MTX as the backbone of any first-line 
regimen, it is much less clear which other agents should be used in case of tumor 
recurrence, absence of response or for patients who cannot tolerate HD MTX. In the 
following section we summarize some of the drugs that are frequently used either alone 
or as part of combined regimens. 
 
Steroids 
Similar to other brain tumors, The administration of corticosteroids results in a reduction 
of the peritumoral edema [47]. However, steroids also have a transient direct anti-tumor 
effect against lymphoma cells through induction of apoptosis which can result in a rapid 
decrease of the size of the tumor mass. When steroids are administered before surgery, 
they may preclude histological confirmation of the diagnosis 
 
Rituximab 
The putative beneficial role of rituximab, a monoclonal antibody targeting the cell surface 
antigen CD20 which is found in the majority of PCNSL, remains a matter of debate. 
Being part of most therapeutic regimens against systemic B cell lymphomas, its activity 
against lymphomas in the CNS is doubtful. CSF levels of rituximab after systemic 
application are approximately 0.1% of serum levels, a phenomenon which is mainly 
caused by the presence of the blood-brain barrier which hampers the penetration of the 
antibody into the CSF [48]. Still, monotherapy with rituximab in the setting of recurrent 
PCNSL was reported to yield occasional radiographic responses in up to 33% of patients 
without major toxicity concerns [49]. This may reflect the partially disrupted blood-brain 
barrier in PCNSL which may still allow the antibody reaching some of brain lymphoma 
cells. Series looking at the efficacy of rituximab when added to a MTX-based regimen 
suggest a certain activity in PCNSL which is associated with increased CR rates that 
may eventually translate into prolonged OS without adding significant toxicity [50, 51]. 
However, these studies have limited value due to their retrospective nature. The results 
of the ongoing prospective HOVON 105 (EudraCT no. 2009-014722-42) and IELSG32 
(NCT01011920) trials which explore the activity of rituximab in a randomized fashion 
need to be awaited. Similarly, the role of intrathecal administration of rituximab has not 
yet been determined (see below). 
 
Temozolomide 
Temozolomide crosses the blood-barrier and has been included in several MTX-based 
regimens (see above). It has been mainly examined in patients with recurrent PCNSL 
who had previously been treated with MTX. Here, single-agent temozolomide was 
typically well tolerated whereas its activity was overall limited with CR rates in the range 
of 20-30% [52, 53]. Temozolomide alone, when used as first-line therapy in elderly 
patients who did not qualify for MTX-based chemotherapy had also only modest activity 
(see below). The efficacy of temozolomide may depend on the activity of the DNA repair 
protein O6-methylguanine DNA methyltransferase (MGMT). In retrospective series, low 
MGMT protein expression examined by immunohistochemistry or high MGMT promoter 
methylation determined by methylation-sensitive high resolution melting (HS-HRM) 
analysis were predictive for response to temozolomide [54, 55]. However, larger series 
examining the predictive or prospective value of the MGMT status in PCNSL are lacking.  
 
Topotecan 
Topotecan is a topoisomerase I inhibitor that has been administered to patients with 
recurrent or MTX-refractory PCNSL. Treatment with topotecan can induce considerable 
response rates but may be associated with significant toxicity [56, 57].  
 
Intrathecal therapy 
 
Dissemination of lymphoma cells into the CSF is a common finding although the reported 
incidence rates are varying most likely due to different methods that were applied for the 
detection of meningeal affection. The presence of lymphoma cells in the CSF is probably 
not a negative prognostic marker [58]. Still, appropriate treatment of the CSF may be a 
prerequisite for long-lasting remissions. MTX administered at doses of 3 g/m2 or higher 
will adequately penetrate through the blood-brain barrier to yield therapeutic CSF levels 
[59]. Therefore, intrathecal therapy is not considered as a standard of care which is 
supported by 2 retrospective analyses suggesting that additional intrathecal treatment 
does not result in prolonged OS compared to patient cohorts that were not treated 
intrathecally [60, 61]. In contrast, very promising results of a trial using a 
polychemotherapy approach including intraventricular therapy with MTX, prednisolone, 
and cytarabine were not reproduced when the intrathecal treatment was omitted [62-64]. 
Intraventricular administration of rituximab has been examined in a small cohort of 
PCNSL patients. The drug was well tolerated but the beneficial effects of this approach 
remain elusive [65]. Application of drugs by an Ommaya reservoir or a similar device are 
frequently associated with infectious complications and require an additional surgical 
procedure. This may be circumvented by the repeated application of drugs by lumbar 
puncture which, however, may not result in an equal distribution of the compound in the 
CSF. Whether the addition of lumbar or intraventricular treatment to MTX-based 
protocols results in prolonged OS needs further investigation and should be assessed 
within appropriate clinical trials. 
 
Elderly patients 
 
Patients over age 60 are commonly referred to as “elderly”. However, some studies 
focusing on elderly patients only include patients who are at least 65 or even 70 years 
old. Owing to this variability it becomes difficult to compare different studies enrolling 
elderly patients. As with younger patients, MTX should be the backbone of any treatment 
concept in elderly patients because of the lack of drugs with similar activity. In the 
elderly, HD-MTX is commonly well tolerated and can be safely administered in most 
patients [66]. Even in patients aged 80 and older, the application of MTX-containing 
regimens was feasible and resulted in long-term survival in some patients [67]. However, 
exceedingly high serum MTX levels, determined by area under the curve (AUC) 
calculation, are associated with reduced survival and should be avoided [68]. Promising 
CR rates can be achieved in elderly patients. However, the durability of these responses 
is reduced compared to younger patients indicating that consolidation is required in 
elderly patients in CR [66]. Again, various compounds have been added to MTX and 
assessed in smaller trials. The combination of MTX with procarbazine and lomustine 
resulted in a median OS of 15.4 months [69] which was only moderately changed to 17.5 
months when rituximab was added in a subsequent trial [70]. A polychemotherapy 
regimen and additional intrathecal chemotherapy yielded a median OS of 14.3 months in 
a study with 50 PCNSL patients who had a median age of 72 years [71]. The 
combination of HD-MTX with temozolomide was reported to be well tolerated and 
resulted in an OS of 25 months [72]. However, a randomized phase II study comparing 2 
different MTX-based regimens suggests higher activity of MPV-A (MTX, procarbazine, 
vincristine and cytarabine) compared to MTX combined with temozolomide [73]. This 
trial, however, was not designed to prove superiority and these results must be 
confirmed in a phase III trial. No convincing treatment strategies are available for elderly 
patients who cannot be treated with HD-MTX. Radiation therapy is active but has several 
limitations as described above. Dose-intensified temozolomide alone has only limited 
efficacy [74]. In summary, similar to younger patients, HD-MTX should be used in the 
elderly whenever possible and considered appropriate. The benefit of further agents that 
are added to MTX remains to be determined.  
 
 
Recurrent or refractory PCNSL 
 
In the situation of recurrent or refractory PCNSL, no standard treatment has been 
defined. Several options are available and the parameters which should be taken into 
account include the performance status of the patient, benefit from prior therapies and 
the interval between last treatment and tumor recurrence. MTX re-challenge is generally 
considered promising in patients who achieved a CR upon MTX-based treatment [75]. In 
contrast, patients whose tumors must be considered refractory to MTX should be offered 
an alternative treatment. Here, various approaches have been assessed. Similar to the 
situation of newly diagnosed PCNSL, the quality of the available studies is rather poor 
and randomized trials are lacking. WBRT is an active treatment in the setting of recurrent 
PCNSL with high response rates which, however, frequently do not translate into long-
lasting remissions [26, 76]. Temozolomide alone is well tolerated but has only modest 
activity [53]. The combination of temozolomide and rituximab was examined within a trial 
that was closed prematurely after a preliminary analysis had suggested disappointing 
activity [77]. Novel approaches include the administration of pemetrexed, a folate 
antimetabolite. In patients with relapsed or refractory PCNSL, it had single-agent activity 
but was also associated with considerable toxicity [78, 79]. Larger trials are required to 
determine the value of pemetrexed in PCNSL in more detail. Finally, HDC with 
subsequent ASCT may be a promising option for selected patients with recurrent PCNSL 
who qualify for such an intense and rather toxic approach [80, 81]. 
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